secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2023-05-25T23:59:59+00:00
Accession:  0001599298-23-000061
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit Therapeutics shareholders elect 8 directors and approve auditor and advisory compensation
--------------------------------------------------------------------------------

- All 8 director nominees elected with >602M votes for each; broker non-votes ~24.1M.
- Ratification of PwC as auditor for FY2023 approved: 626.2M for, 24.7K against.
- Advisory vote on executive compensation approved: 601.0M for, 653.1K against, 472.6K abstentions.
- Meeting held May 23, 2023; all proposals received required stockholder approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929823000061/0001599298-23-000061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929823000061/smmt-20230523.htm
  HTML page:      https://secwatch.observer/filing/0001599298-23-000061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer